Titan Co. announced its stock price experienced abnormal fluctuations, with a cumulative increase exceeding 20% over three trading days. The company clarified that its high-end electronic fabric jet looms are still in the research and development phase and have not generated any sales revenue. Separately, Fosun Pharma's subsidiary received EU approval for two new indications for its drug Serplulimab injection, targeting specific types of advanced esophageal and non-small cell lung cancer. AI
RANK_REASON The cluster contains unrelated news items about a stock fluctuation and a drug approval, lacking a cohesive narrative or significant AI-industry impact.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
